{"id":251361,"date":"2021-11-10T00:00:00","date_gmt":"2021-11-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidmd0085-biopharma-osteopenia-epidemiology-americas\/"},"modified":"2026-03-31T10:41:54","modified_gmt":"2026-03-31T10:41:54","slug":"epidmd0085-biopharma-osteopenia-epidemiology-americas","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0085-biopharma-osteopenia-epidemiology-americas\/","title":{"rendered":"Osteopenia &#8211; Epidemiology &#8211; Americas"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr data-abbreviation-entity=\"7532\" title=\"osteopenia\">OPE<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of <abbr data-abbreviation-entity=\"7532\" title=\"osteopenia\">OPE<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"7532\" title=\"osteopenia\">OPE<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"7532\" title=\"osteopenia\">OPE<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts five <abbr data-abbreviation-entity=\"7532\" title=\"osteopenia\">OPE<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases<\/li>\n<li>Diagnosed non-drug-treated prevalent cases<\/li>\n<li>Undiagnosed prevalent cases<\/li>\n<li>Diagnosed prevalent cases<\/li>\n<li>Diagnosed drug-treated prevalent cases<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251361","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteopenia","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251361\/revisions"}],"predecessor-version":[{"id":283798,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251361\/revisions\/283798"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}